DOP2019000092A - Preparación farmacéutica compleja que comprende amlodipina, losartan y rosuvasta - Google Patents

Preparación farmacéutica compleja que comprende amlodipina, losartan y rosuvasta

Info

Publication number
DOP2019000092A
DOP2019000092A DO2019000092A DO2019000092A DOP2019000092A DO P2019000092 A DOP2019000092 A DO P2019000092A DO 2019000092 A DO2019000092 A DO 2019000092A DO 2019000092 A DO2019000092 A DO 2019000092A DO P2019000092 A DOP2019000092 A DO P2019000092A
Authority
DO
Dominican Republic
Prior art keywords
losartan
rosuvasta
pharmaceutical preparation
active ingredients
present
Prior art date
Application number
DO2019000092A
Other languages
English (en)
Inventor
Hyun Park Jae
Ii Kim Yong
Soo Woo Jong
Taek Im Ho
Jun Cho Hyuk
Ee Lim Sol
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2019000092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of DOP2019000092A publication Critical patent/DOP2019000092A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una preparación de complejo farmacéutica que incluye amlodipina, losartán y rosuvastatina como ingredientes activos. La preparación de complejo farmacéutica de la presente invención que incluye amlodipina, losartán y rosuvastatina como ingredientes activos presenta excelentes características de disolución de todos los ingredientes activos, y también tiene una estabilidad de preparación mejorada. Por lo tanto, la preparación de complejo de la presente invención se puede usar como un agente profiláctico o terapéutico para enfermedades cardiovasculares, que ha asegurado la estabilidad de la calidad incluso cuando se almacena durante un largo período de tiempo.
DO2019000092A 2016-11-15 2019-04-11 Preparación farmacéutica compleja que comprende amlodipina, losartan y rosuvasta DOP2019000092A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160152077 2016-11-15

Publications (1)

Publication Number Publication Date
DOP2019000092A true DOP2019000092A (es) 2019-09-30

Family

ID=62146632

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000092A DOP2019000092A (es) 2016-11-15 2019-04-11 Preparación farmacéutica compleja que comprende amlodipina, losartan y rosuvasta

Country Status (11)

Country Link
CO (1) CO2019004796A2 (es)
CR (1) CR20190265A (es)
DO (1) DOP2019000092A (es)
EA (1) EA201991190A1 (es)
EC (1) ECSP19040732A (es)
MX (1) MX2019005230A (es)
NI (1) NI201900048A (es)
PH (1) PH12019500779A1 (es)
SG (1) SG11201903132YA (es)
WO (1) WO2018093096A2 (es)
ZA (1) ZA201902720B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) * 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물

Also Published As

Publication number Publication date
CO2019004796A2 (es) 2019-05-21
ZA201902720B (en) 2020-08-26
PH12019500779A1 (en) 2019-07-29
MX2019005230A (es) 2019-08-14
EA201991190A1 (ru) 2019-10-31
WO2018093096A3 (en) 2018-07-26
NI201900048A (es) 2019-10-11
WO2018093096A2 (en) 2018-05-24
SG11201903132YA (en) 2019-05-30
CR20190265A (es) 2019-08-22
ECSP19040732A (es) 2019-07-31

Similar Documents

Publication Publication Date Title
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
MX383227B (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
MX386615B (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.
MX390001B (es) Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
ECSP19038749A (es) Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CL2017003437A1 (es) Formulación solida oral que contiene irinotecán y método de preparación de la misma
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
IL266279B1 (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
DOP2019000257A (es) Combinación farmacéutica que comprende ponesimod
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
MX388400B (es) Una composición de dos componentes, que comprende ácido acetilsalicílico.
DOP2019000015A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
ECSP19040732A (es) Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX374540B (es) Desmopresina estabilizada.
PY1749400A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
UA98822U (en) APPLICATION OF KAPIKOR (MELDONIUM DIHYDRATE AND γ-BUTYROBETAINE DIHYDRATE) MEDICINE AS THE ENDOTHELIUM PROTECTOR WITH ANTI-ISCHEMIC EFFECT
UA100710U (xx) Застосування капсул "фітовенол" як гепатопротекторного засобу